Posttransplant rituximab exposure and risk of PTLD in solid organ transplant recipients with EBV DNAemia.

Blood Neoplasia · 2025 · PMC12538014 · PMID 41127866

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

did not reach statistical significanceP = .056so close (0.05 < p ≤ 0.1)

When analyzing rituximab treatment as a time-dependent variable, there was a trend toward association with reduced rate of PTLD that did not reach statistical significance (HR, 0.25; 95% CI, 0.06-1.04; P = .056).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.